Jonathan W. FriedbergMD, MMSc
Dr. Jonathan Friedberg is Director of the James P. Wilmot Cancer Center, Chief of Hematology/Oncology at the University of Rochester Medical Center where he is also Samuel E. Durand Chair in Medicine and Professor of Hematology/Oncology. He received his medical degree from Harvard Medical School. He is also a member of LRF's Scientific Advisory Board.
A winner of several research awards, including the Leukemia and Lymphoma Society's Scholar in Clinical Research, Dr. Friedberg's research interests are in developing novel therapies for patients with Hodgkin and non Hodgkin lymphoma. He is currently involved in early phase trials of several compounds, including fostamatinib disodium and alisertib. Dr. Friedberg, who characterizes both compounds as "exciting," notes that they've already determined that alisertib may have particular efficacy in T-cell lymphomas. "Given limited therapeutic options in that disease, if subsequent trials confirm our initial findings, that would clearly represent an important advance for the field," he says.